[go: up one dir, main page]

WO2007025764A3 - Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel - Google Patents

Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel Download PDF

Info

Publication number
WO2007025764A3
WO2007025764A3 PCT/EP2006/008539 EP2006008539W WO2007025764A3 WO 2007025764 A3 WO2007025764 A3 WO 2007025764A3 EP 2006008539 W EP2006008539 W EP 2006008539W WO 2007025764 A3 WO2007025764 A3 WO 2007025764A3
Authority
WO
WIPO (PCT)
Prior art keywords
clopidogrel
salts
pharmaceutical formulations
monobasic acids
monobasic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/008539
Other languages
English (en)
French (fr)
Other versions
WO2007025764A2 (de
Inventor
Karl-Heinz Doser
Klaus Glaenzer
Uwe Loeffler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karl O Helm AG
Original Assignee
Karl O Helm AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karl O Helm AG filed Critical Karl O Helm AG
Publication of WO2007025764A2 publication Critical patent/WO2007025764A2/de
Publication of WO2007025764A3 publication Critical patent/WO2007025764A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Die vorliegende Erfindung betrifft eine pharmazeutische Formulierung in Form einer Tablette, die als Wirkstoff ein Salz einer monobasischen Säure mit Clopidogrel enthält.
PCT/EP2006/008539 2005-09-01 2006-08-31 Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel Ceased WO2007025764A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE202005013839U DE202005013839U1 (de) 2005-09-01 2005-09-01 Pharmazeutische Formulierung für Salze monobasischer Säuren mit Clopidogrel
DE202005013839.8 2005-09-01

Publications (2)

Publication Number Publication Date
WO2007025764A2 WO2007025764A2 (de) 2007-03-08
WO2007025764A3 true WO2007025764A3 (de) 2007-08-16

Family

ID=35268002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008539 Ceased WO2007025764A2 (de) 2005-09-01 2006-08-31 Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel

Country Status (3)

Country Link
US (1) US20070048370A1 (de)
DE (1) DE202005013839U1 (de)
WO (1) WO2007025764A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100400035C (zh) * 2006-10-18 2008-07-09 深圳信立泰药业股份有限公司 氯吡格雷硫酸盐的固体制剂及其制备方法
EP1970054A3 (de) * 2007-03-14 2009-06-03 Ranbaxy Laboratories Limited Clopidogrel-Tabletten
WO2008129468A2 (en) * 2007-04-20 2008-10-30 Wockhardt Research Centre Pharmaceutical compositions of clopidogrel
WO2010009745A1 (en) * 2008-07-25 2010-01-28 Pharmathen S.A. Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074215A1 (en) * 2003-02-03 2004-09-02 Sunil Sadanand Nadkarni Process for preparation of clopidogrel, its salts and pharmaceutical compositions
WO2005048992A1 (en) * 2003-11-03 2005-06-02 Sandoz Ag Process for preparing clopidogrel compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074215A1 (en) * 2003-02-03 2004-09-02 Sunil Sadanand Nadkarni Process for preparation of clopidogrel, its salts and pharmaceutical compositions
WO2005048992A1 (en) * 2003-11-03 2005-06-02 Sandoz Ag Process for preparing clopidogrel compositions

Also Published As

Publication number Publication date
US20070048370A1 (en) 2007-03-01
WO2007025764A2 (de) 2007-03-08
DE202005013839U1 (de) 2005-10-27

Similar Documents

Publication Publication Date Title
WO2011012816A3 (fr) Formulation pharmaceutique
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2011003853A3 (en) Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
WO2008131114A3 (en) Pharmaceutical formulations containing lipoic acid derivatives
WO2012021715A3 (en) Stable formulations of linaclotide
EP2078731A4 (de) Anti-hb-egf-antikörper als wirkstoff enthaltende pharmazeutische zusammensetzung
WO2004072085A3 (de) Salz einer sulfonsäure mit clopidogrel und dessen verwendung zur herstellung pharmazeutischer formulierungen
WO2010021607A3 (en) Pharmaceutical formulation
EP2045253A4 (de) alpha-AMINOSÄUREDERIVAT UND PHARMAZEUTIKUM, DAS DIESES ALS WIRKSTOFF ENTHÄLT
WO2012022919A3 (fr) Formulations à base de nalbuphine et leurs utilisations
WO2009135593A3 (de) Feste arzneimittelformulierung mit verzögerter freisetzung
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
WO2007014124A3 (en) High drug load formulations and dosage forms
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
WO2009095624A3 (fr) Procede de preparation d'acides dicafeoylquiniques et leur utilisation dans la lutte contre les pucerons
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
WO2008081268A3 (en) Pharmaceutical compositions of entacapone
WO2007125521A3 (en) Polymorphic form of zoledronic acid and processes for their preparation
WO2009049648A3 (en) Improved pharmaceutical composition containing antiviral agent and method for the preparation thereof
EP2722322B8 (de) 1,3-di-oxo-inden-derivat, pharmazeutisch zulässiges salz und optisches isomer davon, herstellungsverfahren dafür und pharmazeutische zusammensetzung mit diesem derivat als antiviralem wirkstoff
WO2007025764A3 (de) Pharmazeutische formulierung für salze monobasischer säuren mit clopidogrel
EP2335698B8 (de) Feste pharmazeutische zubereitung mit grenzartig getrennten wirkstoffen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06777136

Country of ref document: EP

Kind code of ref document: A2